Ascendis Pharma A/S (NASDAQ:ASND) Price Target Lowered to $174.00 at JPMorgan Chase & Co.

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective dropped by JPMorgan Chase & Co. from $180.00 to $174.00 in a report released on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target points to a potential upside of 34.81% from the stock’s current price.

Several other research analysts have also recently weighed in on ASND. Citigroup boosted their price objective on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. TD Cowen boosted their target price on shares of Ascendis Pharma A/S from $157.00 to $160.00 and gave the company a “buy” rating in a research note on Monday. Cantor Fitzgerald restated an “overweight” rating and issued a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, September 16th. Bank of America upped their price objective on Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. Finally, Wells Fargo & Company raised their target price on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $195.92.

Ascendis Pharma A/S Trading Up 0.3 %

ASND stock opened at $129.07 on Wednesday. The stock’s 50 day simple moving average is $135.33 and its 200 day simple moving average is $134.73. Ascendis Pharma A/S has a 12-month low of $85.29 and a 12-month high of $161.00. The stock has a market capitalization of $7.52 billion, a PE ratio of -13.43 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million during the quarter, compared to analysts’ expectations of $94.74 million. On average, research analysts predict that Ascendis Pharma A/S will post -7.2 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP purchased a new position in shares of Ascendis Pharma A/S in the first quarter valued at about $992,000. Price T Rowe Associates Inc. MD lifted its holdings in Ascendis Pharma A/S by 23.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after purchasing an additional 336,976 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Ascendis Pharma A/S by 4,231.4% in the 1st quarter. BNP Paribas Financial Markets now owns 75,540 shares of the biotechnology company’s stock worth $11,419,000 after purchasing an additional 73,796 shares during the period. Evolutionary Tree Capital Management LLC grew its holdings in Ascendis Pharma A/S by 82.3% during the 2nd quarter. Evolutionary Tree Capital Management LLC now owns 24,862 shares of the biotechnology company’s stock valued at $3,391,000 after buying an additional 11,223 shares in the last quarter. Finally, SG Americas Securities LLC raised its position in shares of Ascendis Pharma A/S by 221.0% during the second quarter. SG Americas Securities LLC now owns 6,108 shares of the biotechnology company’s stock valued at $833,000 after buying an additional 4,205 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.